Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: growthvalue who wrote (24482)	8/13/1998 6:40:00 PM
From: Andreas Helke	Respond to of 32384

I think Ligand intends to add value by getting the marketing rights for Ontak from Eli Lilly. The acquisition of Seragen was probably a necessary evil to get the approval of Seragens management for the Ligand Eli Lilly Ontak deal. If Seragen had stayed independent they probably would have insisted on keeping Eli Lilly as their marketing partner. I think the stock market will assign a higher value to 2 different CTCL treatments from one company than they would if they came from competing companies. Investors probably would have doubted that Ligand could successfully compete with Eli Lilly. Andreas

To: growthvalue who wrote (24482)	8/13/1998 6:50:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

<< The ONLY way for LGND to benefit you as a shareholder is to add value. >> In a perfect investment world, this is probably true. But, in this age of high valuations based on revenues, where a lot of stock's PE have been mortgaged out to 2010 and beyond, perception and hype drives a lot of rallies. The market doesn't only recognize value, it recognizes momentum. If the biotech climate improves, (that's a big IF) and LGND gets approval for ONTAK and Panretin Gel, and submits three new NDAs, plus the plethora of other news items, we could start going up. Regards, Bob